Standard Biotools Inc.: Form 10-Q for the period ended Sep 30, 2017
Filed with the SEC on Nov 7, 2017 and accepted by EDGAR at Nov 7, 2017, 17:19 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2017-09-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Cost of revenue | 3 months2017-07-01 to 2017-09-30 | $11.4m | us-gaap:CostOfGoodsSold |
| Cost of revenue | 9 months2017-01-01 to 2017-09-30 | $33.1m | us-gaap:CostOfGoodsSold |
| Research and development | 3 months2017-07-01 to 2017-09-30 | $7.7m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 9 months2017-01-01 to 2017-09-30 | $23.7m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months2017-07-01 to 2017-09-30 | $20.1m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 9 months2017-01-01 to 2017-09-30 | $63.7m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months2017-07-01 to 2017-09-30 | −$15.6m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months2017-01-01 to 2017-09-30 | −$49.6m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2017-07-01 to 2017-09-30 | $1.5m | us-gaap:InterestExpense |
| Interest expense | 9 months2017-01-01 to 2017-09-30 | $4.4m | us-gaap:InterestExpense |
| Income tax | 3 months2017-07-01 to 2017-09-30 | −$735.0k | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months2017-01-01 to 2017-09-30 | −$3.3m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2017-07-01 to 2017-09-30 | −$15.9m | us-gaap:NetIncomeLoss |
| Net income | 9 months2017-01-01 to 2017-09-30 | −$50.1m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2017-07-01 to 2017-09-30 | −$0.46 | us-gaap:EarningsPerShareBasicAndDiluted |
| Diluted EPS | 9 months2017-01-01 to 2017-09-30 | −$1.61 | us-gaap:EarningsPerShareBasicAndDiluted |
| Operating cash flow | 9 months2017-01-01 to 2017-09-30 | −$24.8m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months2017-01-01 to 2017-09-30 | $1.4m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2017-09-30 | $60.9m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2017-09-30 | $96.2m | us-gaap:AssetsCurrent |
| Total assets | At period end2017-09-30 | $292.0m | us-gaap:Assets |
| Current liabilities | At period end2017-09-30 | $31.9m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2017-09-30 | $252.9m | us-gaap:Liabilities |
| Shareholders' equity | At period end2017-09-30 | $39.1m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001162194-17-000159. Last ingested by Listed: Nov 5, 2026, 21:16 ET. Listed shows no prices and gives no investment advice.